Macular Degeneration Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You have a condition called geographic atrophy (a type of damage to the center of the eye) caused by age-related macular degeneration (AMD), in one or both eyes
- Your doctor has already decided that you should be treated with a medication called avacincaptad pegol (ACP), given as an injection into the eye
- You are willing to fill out questionnaires about how your condition affects your daily life
Who may not be able to join:
- You have an active infection in or around either eye
- You have active inflammation (swelling or irritation) inside either eye
- You have had an allergic reaction to avacincaptad pegol (ACP) or any of its ingredients
- You are currently taking part in another research study that involves treatments outside of normal medical care
- You have already received ACP injections in the eye that would be treated in this trial (note: if your other eye has received or is receiving ACP, you may still be eligible — confirm with trial site)
- You have received a different type of eye injection called a complement inhibitor in either eye, unless it has been at least 90 days since your last dose of that medication (confirm with trial site)
⚠️ Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Medical Director, Astellas Pharma Global Development, Inc.
Phone: 800-555-5555
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Number of ACP injections; Duration of treatment; Annual frequency of ACP injection; Reasons for discontinuation of treatment with ACP; Duration of the treatment interval; Site characteristics; Characteristics of patients with geographic atrophy (GA) secondary to AMD beginning treatment with Izervay
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.